Deals this week: Agios Pharma, Sanofi Genzyme and Teleflex

19th May 2016 (Last Updated May 19th, 2016 18:30)

Agios Pharma and Celgene Corporation have entered a co-development agreement to jointly develop and commercialise therapies for the treatment of metabolic immune oncology.

Sanofi Genzyme

Agios Pharma and Celgene Corporation have entered a co-development agreement to jointly develop and commercialise therapies for the treatment of metabolic immune oncology.

According to the agreement, Agios will be responsible for exploratory research, drug discovery and early development, eligible for $200m upfront cash payment and also additional payments for developmental and regulatory milestones. Celgene will receive license to each programme at a fee of $30m per programme, while Agios will receive $169m in milestones per programme.

Celgene may also opt for global license rights to inflammation or autoimmune programmes, for which Agios will receive payment of up to $386m in milestones per programme.

Sanofi Genzyme has entered a research agreement with Johns Hopkins Multiple Sclerosis Centre to develop new drugs for multiple sclerosis.

The agreement enables the partners to jointly develop novel strategies to understand the causes of the disease and its progression, and design new therapeutic technologies and methodologies to treat the neurodegenerative disease.

Teleflex has raised gross proceeds of $400m by selling 4.875% of its senior notes, due on 1 June 2026.

The company plans to use the funds to repay approximately $393m of debts under its revolving credit facility.

Reata Pharma has announced the initial public offering of its 4,000,000 class A common stock shares at a price range between $14 and $16 per share, which will be listed on the NASDAQ Global Market under the symbol RETA.

"The company expects to raise funds of approximately between $56m and $64m through the offering."

The company expects to raise funds of approximately between $56m and $64m through the offering.

Vinson & Elkins are acting as the legal advisors, while Citigroup Global Market, Cowen and Company and Piper Jaffray are acting as joint bookers for the deal.

Nouscom plans to advance its discovery and development of personalised cancer vaccines and tumour selective oncolytic viruses through the funds raised in a series A financing round.

The company has raised $13.6m from the financing, which was co-led by Life Sciences Partners and Versant Venture Management.


Image:Sanofi Genzyme has entered a research agreement with Johns Hopkins Multiple Sclerosis Centre. Photo: Courtesy of Sanofi.